NKGEN BIOTECH, INC.

Other languages NKGen Biotech, Inc. Nyse

Equities

NKGN

US65488A1016

Delayed Nyse Other stock markets 16:00:01 2024-05-16 EDT			5-day change	1st Jan Change
1.14 ^USD	0.00%		-10.40%	-86.27%

04-29	Nkgen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy in Parkinson's Disease	CI
04-29	NKGen Biotech, Inc. announced that it has received $0.55 million in funding from FirstFire Capital Management LLC, Meteora Capital, LLC, Glazer Capital, LLC, Meteora Strategic Capital, LLC, Sandia Investment Managment LP	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nkgen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy in Parkinson's Disease	04-29
NKGen Biotech, Inc. Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit	04-18
NKGen Biotech, Inc. Presents Additional Phase 1 Clinical Trial Data in Alzheimer?s Disease At the Tau2024 Global Conference	03-25
NKGen Biotech, Inc. Announces Resignation of Sangwoo Park as Chairperson of the Board	03-20
NKGen Biotech, Inc. Announces Resignation of Alana Mcnulty as Director and as A Member of Audit Committee, Compensation Committee, and Nomination and Corporate Governance Committee	02-08
NKGen Biotech Doses First Patient in Clinical Trial for Alzheimer's Disease Therapy	12-29
Sector Update: Health Care Stocks Edge Higher Premarket Friday	12-29
NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer's Disease	12-28
NKGen Biotech Gets Canadian Regulator's Clearance to Study NK Cell Therapy for Alzheimer's	12-27
NKGen Biotech Inc. Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer's Disease	12-27
Wall Street Set to Open Higher Friday; Core Inflation Rises 0.3% Matching Forecast	23-10-27
US Futures Mixed as Investors Look Toward Personal Income, Consumer Sentiment Reports	23-10-27
Top Premarket Gainers	23-10-27
Nkgen Biotech Presented Phase I Clinical Trial Data At the 16Th Annual Clinical Trials on Alzheimer's Disease Conference	23-10-26
Sector Update: Health Care Stocks Advance in Late Afternoon Trading	23-10-24
NKGen Biotech Gets FDA Clearance to Start Alzheimer's Disease Trial; Shares Jump	23-10-24
NKGen Biotech, Inc. Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer's Disease	23-10-24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW